Parietaria pollen allergy immunotherapy(Laboratorios LETI SL)(Parietaria pollen allergy immunotherapy(Laboratorios LETI SL))

概要

基本信息

药物类型

变应原提取物

别名

Depigoid Parietaria judaica、Parietaria pollen allergy immunotherapy

靶点-

作用机制

免疫调节剂

治疗领域

免疫系统疾病感染眼部疾病+ [2]

在研适应症-

非在研适应症

变应性结膜炎过敏性鼻炎

原研机构

LETI Pharma SLU

在研机构-

非在研机构

LETI Pharma SLU

最高研发阶段无进展临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Parietaria pollen allergy immunotherapy(Laboratorios LETI SL) 相关的临床试验

NCT01734265 / Completed临床2期

Prospective, Open Uncontrolled Study to Evaluate the Safety of Depigoid With Two Pollen Combinations (Grasses/Olea and Grasses/Parietaria)2000DPP/ml in Patients With Allergic Rhinitis or Rhinoconjunctivitis With or Without Seasonal Asthma.

The primary objective of this study is to evaluate the safety and tolerance of a rush build up administration of Depigoid forte pollen and the first maintenance dose administered 4 weeks later.

开始日期2012-11-01

申办/合作机构

LETI Pharma SLU

NCT00916760 / Completed临床3期

Clinical, Multi-centre, Randomised, Double-blind Placebo-controlled Subcutaneous Immunotherapy Trial With Depigmented, Polymerized Extract of Parietaria Judaica Pollen on Patients With Hypersensitivity to This Pollen

The objective of this trial is to assess the clinical efficacy of the modified extract (depigmented and polymerized with glutaraldehyde) of the subcutaneous injection of Parietaria Judaica pollen in the treatment of patients affected by allergic rhinitis/rhinoconjunctivitis ( with or without episodic asthma) induced by hypersensitivity to grass pollen, evaluating the score regarding symptoms and consumption of the medication.

开始日期2008-02-01

申办/合作机构

LETI Pharma SLU

100 项与 Parietaria pollen allergy immunotherapy(Laboratorios LETI SL) 相关的临床结果

登录后查看更多信息

100 项与 Parietaria pollen allergy immunotherapy(Laboratorios LETI SL) 相关的转化医学

登录后查看更多信息

100 项与 Parietaria pollen allergy immunotherapy(Laboratorios LETI SL) 相关的专利（医药）

登录后查看更多信息

6

项与 Parietaria pollen allergy immunotherapy(Laboratorios LETI SL) 相关的文献（医药）

2018-10-01·Immunotherapy

Tolerability and Positive Efficacy Results after Subcutaneous Immunotherapy with Parietaria Judaica Depot Extract

Article

作者: Colomer, Noelia ; Flores, Isabel ; Martínez, Alberto ; Enrique, Ernesto ; Alba, Pilar ; Gómez-Fernández, María Cruz ; Andreu, Carmen ; Madariaga-Goirigolzarri, Begoña ; de Rojas, Dolores Hernández-Fernandez ; Landeta, Araitz ; Asturias, Juan Andrés

Aim: To evaluate tolerability and efficacy of Parietaria judaica subcutaneous immunotherapy on patients with allergic rhinoconjunctivitis. Patients & methods: 51 patients were assigned to build-up scheme (six increasing doses) of P. judaica depot native extract, plus three maintenance monthly administrations. Results: Out of 470 administered doses, only 3.8% elicited systemic reactions (1.5% nonspecific and 2.3% grade I). Concerning the exploratory efficacy parameters: cutaneous reactivity at the final visit versus baseline was significantly decreased; specific titers of IgG and IgG4 increased significantly and patients showed a significant decrease in the rhinitis symptoms score. Conclusion: P. judaica subcutaneous immunotherapy (Allergovac® depot ROXALL Medicina España S.A., Zamudio, Spain) with an abbreviated up-dosing scheme showed an adequate safety and tolerability profile and induced preliminary efficacy changes.

2005-01-01·Journal of investigational allergology & clinical immunology3区 · 医学

Double-blind, placebo-controlled study of immunotherapy with Parietaria judaica: clinical efficacy and tolerance.

3区 · 医学

Article

作者: Burches, E ; Cisteró-Bahima, A ; Basomba, A ; Martín, S ; Rico, P ; Hernández, D ; Alonso, R ; Muñoz, A ; Peláez, A ; Gandarias, B ; Enrique, E ; Ferrer, M

Allergy to Parietaria causes significant morbidity in most Mediterranean areas. The aim of this study is to investigate the efficacy and tolerance of Parietaria depot extract at 25 BU/mL (1.5 microg/mL Par j 1). We performed a multicenter double-blind, placebo-controlled study in rhinitic patients with/without asthma, sensitized to Parietaria. 42 patients followed 20-month immunotherapy. Clinical efficacy was based on symptom and medication scores and the percentage of healthy days (days without symptoms or medication). Severity of asthma/rhinitis scales, visual analogue scale, evaluation of the treatment by doctors and patients, immediate and delayed cutaneous response and quality of life questionnaires were also studied. The active group showed a sustained decrease in symptoms (p = 0.008), medication (p = 0.009) and both (p = 0.001), and an increase in healthy days (p = 0.001) throughout the study, with a threefold increase of healthy days and almost a three time reduction in medication only after one year of treatment. Asthma and rhinitis severity scales also decreased after immunotherapy, and blinded clinical evaluation by physicians confirmed efficacy in 85% and 77% of the active patients. Patient's self-evaluation returned similar results. None of these changes were observed with placebo. Immediate cutaneous response was significantly reduced at the maintenance phase in the active group and remained reduced throughout the study. Late-phase response after intradermal testing also showed a statistical decrease in actively treated patients. Immunotherapy was well tolerated and every systemic reaction reported was mild. In conclusion, immunotherapy with Parietaria 25 BU/mL is an effective and safe treatment for patients with respiratory allergies.

1996-09-01·Harefuah

[Sublingual immunotherapy].

Article

作者: Nelken, D

We treated 14 patients with severe pollinosis or allergic rhinitis with its specific allergen by the sublingual route. Increasing doses of the allergen were given as drops. There was marked improvement in allergic symptoms in 12. Sneezing, itching of the eyes and rhinitis were practically absent, even in the season and there was substantial reduction in intake of antihistamines as well as in the use of steroid inhalers. Only 1 patient did not improve, while 1 developed severe urticaria to Parietaria judaica vaccine.

100 项与 Parietaria pollen allergy immunotherapy(Laboratorios LETI SL) 相关的药物交易

登录后查看更多信息